{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:19:30Z","timestamp":1760170770542},"reference-count":44,"publisher":"Elsevier BV","issue":"1-3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.schres.2012.06.040","type":"journal-article","created":{"date-parts":[[2012,7,18]],"date-time":"2012-07-18T21:34:09Z","timestamp":1342647249000},"page":"169-174","source":"Crossref","is-referenced-by-count":33,"title":["Cardiovascular risk factors during second generation antipsychotic treatment are associated with increased C-reactive protein"],"prefix":"10.1016","volume":"140","author":[{"given":"Ingrid","family":"Dieset","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigrun","family":"Hope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Bjella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Agartz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingrid","family":"Melle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e5l","family":"Aukrust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Ivar","family":"R\u00f8ssberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole A.","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2012.06.040_bb0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.coph.2011.02.004","article-title":"5-HT and the immune system","volume":"11","author":"Ahern","year":"2011","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.schres.2012.06.040_bb0010","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1176\/ajp.156.11.1686","article-title":"Antipsychotic-induced weight gain: a comprehensive research synthesis","volume":"156","author":"Allison","year":"1999","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.05.009","article-title":"A comparison of schizophrenia outpatients treated with antipsychotics with and without metabolic syndrome: findings from the CLAMORS study","volume":"104","author":"Arango","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2012.06.040_bb0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3109\/07853890.2010.523711","article-title":"Tumor necrosis factor superfamily molecules in acute coronary syndromes","volume":"43","author":"Aukrust","year":"2011","journal-title":"Ann. Med."},{"key":"10.1016\/j.schres.2012.06.040_bb0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.4088\/JCP.v67n0314","article-title":"Sociodemographic characteristics and cardiovascular risk factors in patients with severe mental disorders compared with the general population","volume":"67","author":"Birkenaes","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0025","doi-asserted-by":"crossref","first-page":"917","DOI":"10.4088\/JCP.v68n0614","article-title":"The level of cardiovascular risk factors in bipolar disorder equals that of schizophrenia: a comparative study","volume":"68","author":"Birkenaes","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0035","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.schres.2008.08.030","article-title":"Elevated serum levels of tumor necrosis factor-alpha in clozapine-associated obesity in chronic schizophrenia","volume":"106","author":"Chen","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2012.06.040_bb0040","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1586\/eci.10.48","article-title":"At the crossroad between immunity and metabolism: focus on leptin","volume":"6","author":"Conde","year":"2010","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.schres.2012.06.040_bb0045","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1161\/CIR.0b013e318233bc6a","article-title":"Assessing adiposity: a scientific statement from the American Heart Association","volume":"124","author":"Cornier","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.schres.2012.06.040_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.2600","article-title":"An update on the role of markers of inflammation in atherosclerosis","volume":"17","author":"Corrado","year":"2010","journal-title":"J. Atheroscler. Thromb."},{"key":"10.1016\/j.schres.2012.06.040_bb0055","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.eurpsy.2009.01.005","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)","volume":"24","author":"De Hert","year":"2009","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0060","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.schres.2010.06.002","article-title":"Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naive psychotic sample","volume":"121","author":"Diaz","year":"2010","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2012.06.040_bb0065","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bbi.2006.02.002","article-title":"Cytokines in schizophrenia and the effects of antipsychotic drugs","volume":"20","author":"Drzyzga","year":"2006","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2012.06.040_bb0070","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.bbi.2009.01.018","article-title":"Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease","volume":"23","author":"Engler","year":"2009","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2012.06.040_bb0075","first-page":"1481","article-title":"A case\u2013control study of cardiovascular risk factors and cardiovascular risk among patients with schizophrenia in a country in the low cardiovascular risk region of Europe","volume":"29","author":"Ferreira","year":"2010","journal-title":"Rev. Port. Cardiol."},{"key":"10.1016\/j.schres.2012.06.040_bb0080","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.4088\/JCP.08r04505","article-title":"Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature","volume":"70","author":"Goldstein","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0085","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1176\/appi.ajp.162.1.118","article-title":"Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis","volume":"162","author":"Graham","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0090","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2011.06.004","article-title":"Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model","volume":"131","author":"Hahn","year":"2011","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2012.06.040_bb0095","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jpsychires.2011.04.009","article-title":"Impact of antipsychotics on cytokine production in-vitro","volume":"45","author":"Himmerich","year":"2011","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.schres.2012.06.040_bb0105","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1399-5618.2009.00757.x","article-title":"Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor","volume":"11","author":"Hope","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.schres.2012.06.040_bb0100","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1503\/jpn.090088","article-title":"Osteoprotegerin levels in patients with severe mental disorders","volume":"35","author":"Hope","year":"2010","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.schres.2012.06.040_bb0110","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.pnpbp.2006.09.010","article-title":"High-sensitivity C-reactive protein levels in patients with major depressive disorder and bipolar mania","volume":"31","author":"Huang","year":"2007","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0115","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/YIC.0b013e3283400cd3","article-title":"Relationship between insulin resistance and C-reactive protein in a patient population treated with second generation antipsychotic medications","volume":"26","author":"Kim","year":"2011","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2012.06.040_bb0120","doi-asserted-by":"crossref","first-page":"138","DOI":"10.4088\/JCP.08m04666yel","article-title":"A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia","volume":"71","author":"Levkovitz","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0125","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/ATVBAHA.109.199661","article-title":"Biomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortality","volume":"30","author":"Lieb","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.schres.2012.06.040_bb0130","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0135","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.biopsych.2009.06.005","article-title":"Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study","volume":"66","author":"Meyer","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0140","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0145","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2174\/157016109787455680","article-title":"Visceral adipose tissue and atherosclerosis","volume":"7","author":"Ohman","year":"2009","journal-title":"Curr. Vasc. Pharmacol."},{"key":"10.1016\/j.schres.2012.06.040_bb0150","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1194\/jlr.R600021-JLR200","article-title":"The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk","volume":"48","author":"Popa","year":"2007","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.schres.2012.06.040_bb0155","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.biopsych.2007.09.024","article-title":"Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review","volume":"63","author":"Potvin","year":"2008","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1373\/clinchem.2008.119214","article-title":"C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease","volume":"55","author":"Ridker","year":"2009","journal-title":"Clin. Chem."},{"key":"10.1016\/j.schres.2012.06.040_bb0165","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1902\/jop.2008.080249","article-title":"Inflammation, C-reactive protein, and atherothrombosis","volume":"79","author":"Ridker","year":"2008","journal-title":"J. Periodontol."},{"key":"10.1016\/j.schres.2012.06.040_bb0170","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.bbi.2009.10.015","article-title":"The immunoregulatory role of dopamine: an update","volume":"24","author":"Sarkar","year":"2010","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.schres.2012.06.040_bb0175","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1160\/TH09-05-0297","article-title":"How much is too much? Interleukin-6 and its signalling in atherosclerosis","volume":"102","author":"Schuett","year":"2009","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.schres.2012.06.040_bb0180","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eurpsy.2009.01.001","article-title":"How can antipsychotics cause diabetes mellitus? Insights based on receptor-binding profiles, humoral factors and transporter proteins","volume":"24","author":"Starrenburg","year":"2009","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0185","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nature08186","article-title":"Common variants conferring risk of schizophrenia","volume":"460","author":"Stefansson","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.schres.2012.06.040_bb0190","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1463-1326.2011.01378.x","article-title":"Adipocytes express a functional system for serotonin synthesis, reuptake and receptor activation","volume":"13","author":"Stunes","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.schres.2012.06.040_bb0195","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.4088\/JCP.v67n1002","article-title":"Screening for diabetes and other metabolic abnormalities in patients with schizophrenia and schizoaffective disorder: evaluation of incidence and screening methods","volume":"67","author":"van Winkel","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2012.06.040_bb0200","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1399-5618.2007.00520.x","article-title":"Prevalence of diabetes and the metabolic syndrome in a sample of patients with bipolar disorder","volume":"10","author":"van Winkel","year":"2008","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.schres.2012.06.040_bb0205","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.npp.1301142","article-title":"Atypical antipsychotic drugs directly impair insulin action in adipocytes: effects on glucose transport, lipogenesis, and antilipolysis","volume":"32","author":"Vestri","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.schres.2012.06.040_bb0210","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.brainres.2010.05.060","article-title":"Olanzapine-induced accumulation of adipose tissue is associated with an inflammatory state","volume":"1350","author":"Victoriano","year":"2010","journal-title":"Brain Res."},{"key":"10.1016\/j.schres.2012.06.040_bb0215","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1538-7836.2006.01949.x","article-title":"von Willebrand factor, endothelial dysfunction, and cardiovascular disease","volume":"4","author":"Vischer","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.schres.2012.06.040_bb0220","first-page":"543","article-title":"Hormonal interactions between gut and brain","volume":"10","author":"Zac-Varghese","year":"2010","journal-title":"Discov. Med."}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099641200388X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092099641200388X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T13:29:27Z","timestamp":1687613367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092099641200388X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":44,"journal-issue":{"issue":"1-3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S092099641200388X"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2012.06.040","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]}}}